Imatinib mesylate negatively regulates indoleamine 2,3-dioxygenase expression in tumor cells, reducing immunosuppressive tryptophan metabolites in the tumor bed, hence increasing cytolytic T lymphocytes influx and activation [34]. This evidence concerns the gene IDO2 and neoplasm.